Trastuzumab + taxane (Control) | T-DM1 | T-DM1 + pertuzumab | |||||||
---|---|---|---|---|---|---|---|---|---|
(T-DM1) | (T-DM1 + P) | ||||||||
No. patients / No. patients with PFS event | Median PFS (mo) | No. patients / No. patients with PFS event | Median PFS (mo) | HR vs. trastuzumab + taxane (97.5% CI)a | No. patients / No. patients with PFS event | Median PFS (mo) | HR vs. trastuzumab + taxane (97.5% CI)a | HR vs. T-DM1 + placebo (97.5% CI)a | |
All patientsb | |||||||||
IHC 3+ | 333/209 | 14.4 | 340/215 | 14.6 | 0.93 | 331/195 | 16.7 | 0.83 | 0.90 |
(0.75–1.16) | (0.67–1.04) | (0.72–1.12) | |||||||
IHC 2+ | 27/19 | 12.6 | 25/20 | 7.3 | 1.13 | 29/20 | 8.3 | 1.25 | 0.98 |
(0.55–2.32) | (0.61–2.59) | (0.48–2.02) | |||||||
IHC 2+/3+ patients combinedc | |||||||||
Focal IHC 2+/3+ (10–29%)d | 14/8 | 12.4 | 12/10 | 6.4 | 1.51 | 15/12 | 7.5 | 1.41 | 1.00 |
(0.52–4.40) | (0.50–3.94) | (0.38–2.65) | |||||||
Heterogeneous IHC 2+/3+ (30–79%) | 35/27 | 10.6 | 37/25 | 8.3 | 1.04 | 33/20 | 6.3 | 1.11 | 0.91 |
(0.57–2.17) | (0.46–1.78) | ||||||||
(0.55–1.94) | |||||||||
Homogeneous IHC 2+/3+ (≥80%) | 311/193 | 14.6 | 316/200 | 14.7 | 0.92 | 312/183 | 17.8 | 0.82 | 0.89 |
(0.65–1.04) | (0.71–1.13) | ||||||||
(0.74–1.16) | |||||||||
IHC 3+ patients only | |||||||||
Focal IHC 3+ (10–29%)d | 9/5 | 8.3 | 11/7 | 8.3 | 1.20 | 8/7 | 4.2 | 5.11 | 2.28 |
(0.32–4.50) | (0.99–26.40) | (0.60–8.71) | |||||||
Heterogeneous IHC 3+ (30–79%) | 44/29 | 10.5 | 45/34 | 10.0 | 1.15 | 29/16 | 17.8 | 0.79 | 0.65 |
(0.65–2.03) | (0.39–1.60) | (0.33–1.29) | |||||||
Homogeneous IHC 3+ (≥80%) | 280/175 | 14.6 | 284/174 | 15.2 | 0.89 | 294/172 | 17.7 | 0.82 | 0.92 |
(0.70–1.14) | (0.65–1.05) | (0.73–1.17) |